MX2023005928A - Moduladores de malt-1. - Google Patents
Moduladores de malt-1.Info
- Publication number
- MX2023005928A MX2023005928A MX2023005928A MX2023005928A MX2023005928A MX 2023005928 A MX2023005928 A MX 2023005928A MX 2023005928 A MX2023005928 A MX 2023005928A MX 2023005928 A MX2023005928 A MX 2023005928A MX 2023005928 A MX2023005928 A MX 2023005928A
- Authority
- MX
- Mexico
- Prior art keywords
- malt
- modulators
- compounds
- formula
- syndromes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Holo Graphy (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2018412.3A GB202018412D0 (en) | 2020-11-23 | 2020-11-23 | Malt-1 modulators ii |
| PCT/GB2021/053031 WO2022106857A1 (en) | 2020-11-23 | 2021-11-23 | Malt-1 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005928A true MX2023005928A (es) | 2023-09-07 |
Family
ID=74046962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005928A MX2023005928A (es) | 2020-11-23 | 2021-11-23 | Moduladores de malt-1. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250051327A1 (enExample) |
| EP (1) | EP4247492A1 (enExample) |
| JP (1) | JP2023550122A (enExample) |
| KR (1) | KR20230112678A (enExample) |
| CN (1) | CN116528857A (enExample) |
| AU (1) | AU2021381009A1 (enExample) |
| CA (1) | CA3196526A1 (enExample) |
| CO (1) | CO2023007626A2 (enExample) |
| GB (1) | GB202018412D0 (enExample) |
| IL (1) | IL303036A (enExample) |
| MX (1) | MX2023005928A (enExample) |
| WO (1) | WO2022106857A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| EP4638458A1 (en) * | 2022-12-23 | 2025-10-29 | Janssen Pharmaceutica NV | Malt1 inhibitors |
| JP2026526665A (ja) * | 2023-06-30 | 2026-08-10 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤 |
| CN122003418A (zh) * | 2023-09-11 | 2026-05-08 | 薛定谔公司 | 作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物 |
| WO2025223516A1 (zh) * | 2024-04-24 | 2025-10-30 | 首药控股(北京)股份有限公司 | 一种抑制剂杂环化合物 |
| WO2025223551A1 (en) * | 2024-04-26 | 2025-10-30 | Janssen Pharmaceutica Nv | Formulations, crystalline forms and dosage regimens of a malt1 inhibitor |
| WO2025224298A1 (en) * | 2024-04-26 | 2025-10-30 | Janssen Pharmaceutica Nv | Inhibitors of malt1 and methods of their use |
| WO2026003045A1 (en) | 2024-06-26 | 2026-01-02 | Janssen Pharmaceutica Nv | Synthesis of a malt1 inhibitor |
| WO2026003043A1 (en) * | 2024-06-26 | 2026-01-02 | Janssen Pharmaceutica Nv | Malt1 inhibitors |
| WO2026003051A1 (en) * | 2024-06-26 | 2026-01-02 | Janssen Pharmaceutica Nv | Crystalline forms |
| WO2026003039A1 (en) * | 2024-06-26 | 2026-01-02 | Janssen Pharmaceutica Nv | Malt1 inhibitors |
| WO2026003049A1 (en) * | 2024-06-26 | 2026-01-02 | Janssen Pharmaceutica Nv | Malt1 inhibitors |
| WO2026017148A1 (zh) * | 2024-07-19 | 2026-01-22 | 上海拓界生物医药科技有限公司 | 一种malt1抑制剂及其制备方法和用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012240D0 (en) | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
| DE10132686A1 (de) * | 2001-07-05 | 2003-01-16 | Boehringer Ingelheim Pharma | Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US7462614B2 (en) * | 2003-04-01 | 2008-12-09 | Smithkline Beecham Corporation | Imidazotriazine compounds |
| PT2401256E (pt) * | 2009-02-26 | 2013-05-13 | Boehringer Ingelheim Int | Compostos como antagonistas da bradicinina b1 |
| GB0920382D0 (en) | 2009-11-20 | 2010-01-06 | Univ Dundee | Design of molecules |
| WO2012143796A2 (en) * | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| UY34616A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. |
| US9493481B2 (en) * | 2012-02-23 | 2016-11-15 | Vanderbilt University | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2015098991A1 (ja) * | 2013-12-26 | 2015-07-02 | 東レ株式会社 | Ｎ－アルキルアミド誘導体及びその医薬用途 |
| JP6545197B2 (ja) | 2014-05-28 | 2019-07-17 | ノバルティス アーゲー | 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用 |
| US10124004B2 (en) * | 2015-05-29 | 2018-11-13 | Teijin Pharma Limited | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
| WO2017027717A1 (en) * | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| EP3374361A1 (en) | 2015-11-13 | 2018-09-19 | Novartis AG | Novel pyrazolo pyrimidine derivatives |
| JP6902040B2 (ja) * | 2016-01-28 | 2021-07-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 免疫チェックポイント阻害剤の効力を増強する方法 |
| RU2019108717A (ru) * | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| JP2018135274A (ja) * | 2017-02-20 | 2018-08-30 | Ａｇｃ株式会社 | 多環芳香族炭化水素を光触媒とするフルオロメチル基含有化合物の製造方法 |
| JP6891047B2 (ja) * | 2017-05-31 | 2021-06-18 | 国立大学法人 名古屋工業大学 | 光学活性トリフルオロメチル基含有アミノ酸誘導体の製造方法 |
| WO2018226150A1 (en) * | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
| BR112021009994A2 (pt) | 2018-11-28 | 2021-08-17 | Takeda Pharmaceutical Company Limited | composto, e, medicamento |
| WO2022081995A1 (en) * | 2020-10-16 | 2022-04-21 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| WO2022081967A1 (en) * | 2020-10-16 | 2022-04-21 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
-
2020
- 2020-11-23 GB GBGB2018412.3A patent/GB202018412D0/en not_active Ceased
-
2021
- 2021-11-23 WO PCT/GB2021/053031 patent/WO2022106857A1/en not_active Ceased
- 2021-11-23 IL IL303036A patent/IL303036A/en unknown
- 2021-11-23 MX MX2023005928A patent/MX2023005928A/es unknown
- 2021-11-23 CN CN202180078754.7A patent/CN116528857A/zh active Pending
- 2021-11-23 US US18/253,572 patent/US20250051327A1/en active Pending
- 2021-11-23 EP EP21836594.8A patent/EP4247492A1/en active Pending
- 2021-11-23 JP JP2023530634A patent/JP2023550122A/ja active Pending
- 2021-11-23 CA CA3196526A patent/CA3196526A1/en active Pending
- 2021-11-23 AU AU2021381009A patent/AU2021381009A1/en active Pending
- 2021-11-23 KR KR1020237021035A patent/KR20230112678A/ko active Pending
-
2023
- 2023-06-09 CO CONC2023/0007626A patent/CO2023007626A2/es unknown
-
2025
- 2025-12-18 US US19/424,423 patent/US20260109698A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023007626A2 (es) | 2023-08-18 |
| WO2022106857A1 (en) | 2022-05-27 |
| US20250051327A1 (en) | 2025-02-13 |
| EP4247492A1 (en) | 2023-09-27 |
| US20260109698A1 (en) | 2026-04-23 |
| AU2021381009A1 (en) | 2023-06-08 |
| GB202018412D0 (en) | 2021-01-06 |
| IL303036A (en) | 2023-07-01 |
| KR20230112678A (ko) | 2023-07-27 |
| CA3196526A1 (en) | 2022-05-27 |
| CN116528857A (zh) | 2023-08-01 |
| JP2023550122A (ja) | 2023-11-30 |
| AU2021381009A9 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013013A (es) | Moduladores de proteina cinasa c (pkc)-theta. | |
| MX2023013012A (es) | Moduladores de proteina cinasa c (pkc)-theta. | |
| CO2023007626A2 (es) | Moduladores de malt-1 | |
| PH12021552759A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| PH12020552206A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| TN2019000192A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| PH12020552207A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| PH12020550524A1 (en) | Modulators of the integrated stress pathway | |
| MY207223A (en) | Prodrug modulators of the integrated stress pathway | |
| UY38685A (es) | Moduladores de la vía de tensión integrada | |
| MX2025007384A (es) | Inhibidores de malt1 | |
| PH12021552555A1 (en) | Dihydroorotate dehydrogenase inhibitors | |
| MX2020006290A (es) | Dinucleotidos ciclicos como agonistas de sting. | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| MX2023008589A (es) | Compuestos moduladores de gcn2 y usos de los mismos. | |
| MX2021012417A (es) | Anillos de piridina que contienen derivados como inhibidores de malt1. | |
| CA3196916A1 (en) | Modulators of the integrated stress pathway | |
| PH12020552172A1 (en) | Cyclic dinucleotides as sting agonists | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| WO2021226206A3 (en) | Cannabinoid receptor type 2 (cb2) modulators and uses thereof | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| MX2025007469A (es) | Moduladores lsd1 | |
| MX2023003035A (es) | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme. | |
| MX2021014582A (es) | Derivados de diazepinona como moduladores del ensamblaje de la capside. | |
| MX2021014580A (es) | Derivados heterociclos condensados como moduladores de ensamblaje de la capside. |